$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer

2014-02

2015-03

2015-03

40

Study Overview

Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Pancreatic Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the Pancreatic Cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the Pancreatic Cancer patient using a similar protocol as investigators reported . Aim 1: To demonstrate, in vitro, the relative cellular anti-Pancreatic Cancer CSC immunity induced by Pancreatic Cancer CSC-DC primed cytotoxic T cells. Aim 2: To determine, in vitro, specific binding and lysis of Pancreatic Cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with Pancreatic Cancer CSC-DC.

  • Neoplasms, Pancreas
  • BIOLOGICAL: cancer stem cell vaccine
  • CLP-001
  • 201401 (OTHER_GRANT Identifier) (OTHER_GRANT: The research fund of Fuda cancer hospital in Guangzhou)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2014-02-25  

N/A  

2015-06-01  

2014-02-26  

N/A  

2015-06-03  

2014-02-28  

N/A  

2014-02  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
Single

Arms and Interventions

Participant Group/ArmIntervention/Treatment
PLACEBO_COMPARATOR: non-cancer stem cell vaccine

The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

BIOLOGICAL: cancer stem cell vaccine

EXPERIMENTAL: giving low dose vaccine

The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

BIOLOGICAL: cancer stem cell vaccine

EXPERIMENTAL: giving middle dose vaccine

The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

BIOLOGICAL: cancer stem cell vaccine

EXPERIMENTAL: giving high dose vaccine

The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

BIOLOGICAL: cancer stem cell vaccine

Primary Outcome MeasuresMeasure DescriptionTime Frame
The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse eventsup to 3 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements1 month

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • 1. Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas. The site of the primary lesion should be confirmed endoscopically, radiologically, or surgically to be in the pancreas.

    • 2. Patients must be deemed unresectable due to involvement of critical vasculature, adjacent organ invasion, presence of metastasis, or other medical condition making surgical resection unfavorable.
    3. Patients must have a primary or metastatic lesion measurable in at least one dimension by RECIST criteria within 4 weeks prior to entry of study .
    4. More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
    5. Life expectancy of >3 months. 6. Karnofsky performance status >70%. 7. The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation):
  • Hemoglobin: Within normal range according to institutional standards;
  • Absolute leukocyte count: Within normal range according to institutional standards;
  • Absolute lymphocyte count: Within normal range according to institutional standards;
  • Platelet count: Within normal range according to institutional standards;
  • Alanine aminotransferase: ≤ 2.5 x Upper Limit of Normal (ULN);
  • Aspartate aminotransferase: ≤ 2.5 x ULN;
  • Total bilirubin: ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN;
  • Serum creatinine: 1.5 x ULN;
  • Calculated creatinine clearance: > 50 mL/min . 8. Age >18 years. 9. No history of autoimmune diseases. 10. Ability to understand the study protocol and a willingness to sign a written informed consent document.

    • Exclusion Criteria:
    - 1. Patients receiving anticoagulation therapy. 2. Patients who have received prior gemcitabine or radiation therapy to the pancreatic bed 3. Patients receiving any other investigational agents. 4. Patients with known brain metastases will be excluded because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse effects.
    5. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
    6. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 7. level 3 hypertension; 8. severe coronary disease; 9. myelosuppression; 10. respiratory disease; 11. brain metastasis; 12. chronic infections

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • University of Michigan
  • : ,

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince ME, Xu Y, Zhang XL, Huang S, Chang AE, Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012 Apr 1;72(7):1853-64. doi: 10.1158/0008-5472.CAN-11-1400.
NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate